There’s gold in dem hills

Some time ago in an interview with a well regarded cancer expert, the topic of learning more from patients tumours came up, and with it some of the challenges inherent in the process, such as access to biopsy samples.

If you think about, while post mortems can tell us why an individual person’s lesions stopped responding to a particular therapy, it’s only when we have huge broad (many tumour types) and deep (primary and metastatic lesions) in datasets with a richness of data that we can truly learn about patterns and trends.

What truly drives metastases and when?  Can we determine novel and more accurate biomarkers earlier than we currently have?

There’s plenty of gold nuggets to be found in the latest genomics research…

BSB subscribers can read our latest commentary – you can either log-in or click to access.

This content is restricted to subscribers

Posted by